Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIVEDIFF: EXL01 to prevent recurrent Clostridioides difficile infection in high-risk adults
2023-506232-32-00Phase 2Authorised
- Sponsor
- Hospices Civils de Lyon
- Start
- Nov 2023
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of exl01 in Clostridioides difficile colitis (CDI) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoints: Serious adverse events and treatment discontinuation due to adverse events and Recurrence of toxigenic Clostridioides difficile infection at week 8. Planned start Nov 2023; status: authorised.
02
Drugs
exl01
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2023-506232-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506232-32-00.